Interleukin-12 gene therapy (Valentis)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterleukin-12 gene therapy (Valentis)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocytes stimulantsNatural killer cells stimulantsInterleukin-12 stimulants
TargetsInterleukin-12
Therapy Area/IndicationsHead and Neck NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesValentisUniversity Of PennsylvaniaDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteValentisF. Hoffmann-La Roche Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A